Exelixis Inc is a biopharmaceutical company focused on developing innovative therapies for patients with cancer. The company primarily engages in the discovery, development, and commercialization of small molecule drugs that target key pathways involved in cancer cell growth and survival. Through its research and clinical development programs, Exelixis aims to provide effective treatment options that improve patient outcomes and enhance the quality of life for individuals battling various forms of cancer. The company's commitment to oncology is evident in its robust pipeline of investigational drugs and its ongoing collaborations with other organizations in the healthcare sector. Read More
Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.
EXELIXIS (NASDAQ:EXEL) offers strong growth, fair valuation, and financial health, fitting the "Affordable Growth" strategy with high scores in profitability and low bankruptcy risk.
EXELIXIS INC (EXEL) combines strong growth fundamentals—high profitability, solid financials, and rising revenue—with bullish technical signals, making it a promising breakout candidate for investors.
Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) for the treatment of adult patients with unresectable or metastatic, well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This approval follows the positive opinion received from the European Medicines Agency’s Committee for Medicinal Products for Human Use in June 2025 and allows for the marketing of CABOMETYX in this indication in all 27 member states of the European Union (EU), Norway, Liechtenstein and Iceland.
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors and breakout traders.
EXELIXIS (NASDAQ:EXEL) shows strong technical and fundamental growth, meeting Minervini’s Trend Template criteria with high earnings momentum and a bullish chart setup.
Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2025 financial results will be released on Monday, July 28, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.
EXELIXIS INC (NASDAQ:EXEL) shows strong growth, profitability, and financial health, making it a standout for investors following Louis Navellier’s strategy. With high earnings surprises and accelerating margins, EXEL presents a compelling case.
EXELIXIS INC (NASDAQ:EXEL) offers strong growth potential at a reasonable valuation, backed by solid profitability and a debt-free balance sheet. A compelling pick for growth investors.
EXELIXIS (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, zero debt, and robust growth prospects, making it a candidate for value investors.
